NCT00903227View on ClinicalTrials.gov

Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
AsthmaAllergic Rhinitis
Interventions
DRUG

Fluticasone Evohaler pMDI

One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)

DRUG

Placebo

1 puff of inhaled Placebo twice a day

DRUG

Fluticasone Evohaler

One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)

DRUG

Placebo intranasal spray

placebo intranasal spray 2 squirts each nostril once a day

DRUG

fluticasone propionate (Flixonase®)

intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts

Trial Locations (1)

DD1 9SY

Asthma and Allergy Research Group, Ninewells Hospital and University of Dundee, Dundee

All Listed Sponsors
lead

University of Dundee

OTHER

NCT00903227 - Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis | Biotech Hunter | Biotech Hunter